Fusion Antibodies Share Discussion Threads

[tomboyb] 18/9/2020 10:36

Getting a bit hot under the collar -

[tidy 2] 18/9/2020 10:33

Compare cap here to the recent star covid stocks AVCT NCYT SNG All over £300m cap from FABs low level cap of £32m

[tidy 2] 18/9/2020 10:27

hTTps://www.fusionantibodies.com/collaborations/

[superg1] 18/9/2020 10:27

Acuere

Was that the general antibody type news re progress.

I though Fab would see interest due to that but some sold.

It forces the point that the market is pretty much oblivious to FAB and its tech. No dob that will change in the coming days and weeks as the usual crew catch on.

Some had flirted around it like Doc but the 9.30 news will have caught many out.

The underlying business looks interesting before Covid featured.

In theory a long way to go for the share price in the coming years on the underlying business but Covid will accelerate that.

In theory big pharmas will sign up as they will want a finger in all the pies.

[allstars001] 18/9/2020 10:26

Surely strong buys to come?

[tomboyb] 18/9/2020 10:25

acuere18 Sep '20 - 10:14 - 174 of 175
0 1 0
No time to check but is this related to the Eli Lilly announcement this week?

no idea -

if it is then it could be big big -

will take a look -

[tidy 2] 18/9/2020 10:18

hTTps://twitter.com/andy47640/status/1306884790520606729?s=21

[acuere] 18/9/2020 10:14

No time to check but is this related to the Eli Lilly announcement this week?

[superg1] 18/9/2020 10:12

Nice to see.

The covid sleeper they all missed with most likely the best answer of the lot, neutralising antibodies to treat patents.

The antigen side in that news looks lucrative.

FAB already supply various antibodies to 8 of the top 10 (by revenue) Pharma companies.

[tomboyb] 18/9/2020 10:10

Dr Richard Buick, CTO of Fusion Antibodies, said: "We are committed to developing the highest quality reagents to be used in the fight against COVID-19. Recent lab studies have shown that results using our antigens correlate 100% with clinical data from patients infected with SARS-CoV-2. We are using these high quality antigens to pan our human antibody library for SARS-CoV-2 neutralising antibodies, and we are delighted to now be able to make these antigens available to companies and researchers around the world to Test, Track & Trace this disease."

Paul Kerr, CEO of Fusion Antibodies said: "According to the FDA, antigen tests will play a critical role in the fight against COVID-19 and like many other companies within the antibody world at large, we are leveraging our antigen expertise to create multiple antigens to be used against the COVID-19 pandemic. "

[tomboyb] 18/9/2020 10:08

8/09/2020 9:31am
UK Regulatory (RNS & others)

Fusion Antibodies (LSE:FAB)
Intraday Stock Chart

Friday 18 September 2020

Click Here for more Fusion Antibodies Charts.
TIDMFAB

RNS Number : 4285Z

Fusion Antibodies PLC

18 September 2020

Fusion Antibodies plc

("Fusion" or the "Company")

Update on R&D programme

Progress with coronavirus antigen and Library

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on the Company's research and development programme.

The Company's proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") continues to progress according to plan. The Company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins. These antigens have been tested by external partners against patient blood samples and show a 100% correlation with results from a leading certified benchmark test.

The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.

The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates.

Dr Richard Buick, CTO of Fusion Antibodies, said: "We are committed to developing the highest quality reagents to be used in the fight against COVID-19. Recent lab studies have shown that results using our antigens correlate 100% with clinical data from patients infected with SARS-CoV-2. We are using these high quality antigens to pan our human antibody library for SARS-CoV-2 neutralising antibodies, and we are delighted to now be able to make these antigens available to companies and researchers around the world to Test, Track & Trace this disease."

Paul Kerr, CEO of Fusion Antibodies said: "According to the FDA, antigen tests will play a critical role in the fight against COVID-19 and like many other companies within the antibody world at large, we are leveraging our antigen expertise to create multiple antigens to be used against the COVID-19 pandemic. "

Enquiries:

[tidy 2] 18/9/2020 10:08

Game changer news for Both FAB and covid. The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates.

[tomboyb] 18/9/2020 10:06

2 quid plus -

[timbo003] 18/9/2020 09:50

Indeed, positive progress

At the very least, it provides an excellent showcase for the Mammalian Antibody Library Discovery Platform

[acuere] 18/9/2020 09:44

Excellent RNS.

This could get really exciting now.

[timbo003] 17/9/2020 11:29

>>>GWR

I doubt if they are involved with Lilly on this, but they wouldn't be able to tell us even if they were.

[gwr7] 17/9/2020 10:46

FAB aren't working with Lilly on that drug trial. The Telegraph has reported good preliminary results but as yet there is no statistical significance so could be due to chance. Integrity has flown out of the window with health companies. They realise covid is an opportunity to ramp themselves on twitter. We had the same last week with the greasy bloke at BBI.

[timbo003] 17/9/2020 10:24

Now if FAB were working with Lilly and were to provide them with a vital step for the efficient synthesis and scale up an antibody treatment against COVID-19 and negotiate a 1% royalty on future sales, then that would be more exciting. However, one of the major difficulties is to get a (cash rich) big pharma like Lilly to give away 1% of future sales, they would just rather pay a bit more for fee for service (and who can blame them)

[timbo003] 17/9/2020 09:47

I assume this morning's rise is due to the twitter rampers pumping away on FAB's retweet ( ) of this story in today's telegraph (about an hour ago), so a short lived rise I suspect:

[cumnor] 17/9/2020 09:25

Probably something to do with this yesterday-but FAB not involved I think. Still shows the importance of antibody research.

[money4me] 17/9/2020 09:19

Not a clue but I like it

[paraguay] 17/9/2020 09:16

looks like some upward movement yesterday and today. Any ideas why - or is it just talk of all this testing?

[superg1] 04/9/2020 10:35

On the Sp moves

There are only something like 26 mill shares with about 70 mill of those taken up by major holders.

The MMs carry no stock so simply react to buy sells and hence smalls buys and sells can cause big moves.

Certainly a very interesting company to research and understand before potential market interest.

Many will think BIO = Big fund raises and big spends. It's no the case at FAB they avoided that route early on and have chosen their path which adds the value but doesn't carry the risk.